What failed BIA 10–2474 Phase I clinical trial? Global speculations and recommendations for future Phase I trials
Rimplejeet Kaur1, Preeti Sidhu1, Surjit Singh1★★ Corresponding author
Volume 7, Issue 3 · pp. 120–121 · PUBLISHED 2016 · DOI: 10.4103/0976-500X.189661
ABSTRACT
It is now known through the various studies that the endocannabinoids have dual role in human health. On the one hand, they contribute to the etiology of some diseases; on other they play “protective role” in some other disease states. This evoked the interest in developing exogenous drugs that can modulate cannabinoid system.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Kaur, R., Sidhu, P., & Singh, S. (2016). What failed BIA 10–2474 Phase I clinical trial? Global speculations and recommendations for future Phase I trials. Journal of Pharmacology and Pharmacotherapeutics, 7(3), 120–121. https://doi.org/10.4103/0976-500X.189661